Literature DB >> 7814282

Comparison of methodologies used in assessing the postantibiotic effect.

F M MacKenzie1, I M Gould, D G Chapman, D Jason.   

Abstract

The postantibiotic effect (PAE) of the carbapenem antibiotic meropenem was determined for the reference strains of Escherichia coli NCTC 4174 and E. coli NCTC 12210. Regrowth of bacteria after antibiotic exposure was determined by viable counting and bioluminescence alone and in combination with an impedance technique and a morphological technique was also employed. Different methods of calculating the PAE were also used. After exposure of E. coli to 0.1-100 x MIC of meropenem for 2 h, concentration dependent differences in counts by bioluminescence, and viable counting were observed, the latter always being lower. The unexposed control of E. coli NCTC 4174 yielded counts of 1.1 x 10(6) +/- 1.1 x 10(5) and 1.3 x 10(6) +/- 4.7 x 10(5) by viable counting and bioluminescence respectively and E. coli NCTC 12210 gave counts of 4.2 x 10(6) +/- 1.8 x 10(6) and 1.1 x 10(7) +/- 4.3 x 10(6) by the same methods. After exposure to 100 x MIC of meropenem, NCTC 4174 yielded counts of 1.28 x 10(3) +/- 5.35 x 10(2) and 2.59 x 10(5) +/- 8.61 x 10(4) and NCTC 12210 gave counts of 5.22 x 10(3) +/- 9.74 x 10(2) and 5.21 x 10(6) +/- 1.45 x 10(6) by viable counting and bioluminescence, respectively. The discrepancies were due to the inability of the viable counting procedure to detect spheroplasts. Falsely low post exposure counts led to falsely low determinations of PAE by viable counting alone and in combination with the impedance technique.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814282     DOI: 10.1093/jac/34.2.223

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  9 in total

1.  Variation in postantibiotic effect of clindamycin against clinical isolates of Staphylococcus aureus and implications for dosing of patients with osteomyelitis.

Authors:  I B Xue; P G Davey; G Phillips
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

Review 2.  Meropenem: a review of its use in patients in intensive care.

Authors:  M Hurst; H M Lamb
Journal:  Drugs       Date:  2000-03       Impact factor: 9.546

3.  Postantibiotic effects and Burkholderia (Pseudomonas) pseudomallei: evaluation of current treatment.

Authors:  A L Walsh; M D Smith; V Wuthiekanun; N J White
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

4.  Postantibiotic effect of meropenem on members of the family Enterobacteriaceae determined by five methods.

Authors:  F M MacKenzie; I M Gould; D G Chapman; D Jason
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

5.  Pharmacodynamic effects of antibiotics and antibiotic combinations on growing and nongrowing Staphylococcus epidermidis cells.

Authors:  E Svensson; H Hanberger; L E Nilsson
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

Review 6.  Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  L R Wiseman; A J Wagstaff; R N Brogden; H M Bryson
Journal:  Drugs       Date:  1995-07       Impact factor: 9.546

Review 7.  Safety of imipenem/cilastatin in neurocritical care patients.

Authors:  Jason Hoffman; Jason Trimble; Gretchen M Brophy
Journal:  Neurocrit Care       Date:  2008-12-31       Impact factor: 3.210

8.  Short-term topical therapy of experimental tinea pedis in guinea pigs with lanoconazole, a new imidazole antimycotic agent.

Authors:  Y Niwano; T Tabuchi; K Kanai; H Hamaguchi; K Uchida; H Yamaguchi
Journal:  Antimicrob Agents Chemother       Date:  1995-10       Impact factor: 5.191

9.  Use of the microbial growth curve in postantibiotic effect studies of Legionella pneumophila.

Authors:  Raymond P Smith; Aldona L Baltch; Phyllis B Michelsen; William J Ritz; Richard Alteri
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.